On October 28, 2021 CiMaas, reported together with the Maastricht University Medical Center+ and the University Medical Center Utrecht have received a subsidy of € 1,48 million to further develop Natural Killer Cell therapy for breast cancer (Press release, CiMaas, OCT 28, 2021, View Source [SID1234593964]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These funds will allow the consortium to further develop their NK cell expansion technology as well as creating Next generation NK cells. These cells will further be tested in human organoid cultures and proper in vivo models.

The subsidy is provided by the Dutch KWF Cancer Research Fundfonds for the national initiative LSH-TKI (Life Science Health, Top Consortia for Knowledge and Innovation) Health-Holland.